Impact of KRAS Mutations and Co-mutations on Clinical Outcome in Pancreatic Ductal Adenocarcinoma

Abstract The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 PDAC patients (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS mutation status and subtypes were prognostic (p<0.001). Relative to patients with KRAS wildtype tumors (median OS 38 months), patients with KRAS G12R had a similar OS (median 34 months), while patients with KRAS Q61 and KRAS G12D mutated tumors had shorter OS (median 20 months [HR: 1.9, 95% CI 1.2-3.0, p=0.006] and 22 months [HR: 1.7, 95% CI 1.3-2.3, p<0.001], respectively). There was enrichment of KRAS G12D mutation in metastatic tumors (34% vs 24%, OR: 1.7, 95% CI 1.2-2.4, p=0.001) and enrichment of KRAS G12R in well and moderately differentiated tumors (14% vs 9%, OR: 1.7, 95% CI 1.05-2.99, p=0.04). Similar findings were observed in the external validation cohort (PanCAN’s Know Your Tumor® dataset, n=408).

[1]  R. Yaeger,et al.  Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Dooms,et al.  Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100 , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Maitra,et al.  Pancreatic cancer: Advances and challenges , 2023, Cell.

[4]  Michael L. Wang,et al.  Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations , 2023, Blood Cancer Journal.

[5]  J. Shen,et al.  Survival improvement for patients with metastatic colorectal cancer over twenty years , 2023, npj Precision Oncology.

[6]  T. Burns,et al.  Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. , 2022, The New England journal of medicine.

[7]  P. Hegde,et al.  Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors , 2022, NPJ precision oncology.

[8]  J. Christensen,et al.  Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer , 2022, Cancer discovery.

[9]  E. Petricoin,et al.  Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. , 2022, Cancer research.

[10]  C. Chen,et al.  Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors , 2022, Cancers.

[11]  I. Shih,et al.  Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response , 2022, Journal of Biomedical Science.

[12]  C. Pritchard,et al.  KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas , 2022, The oncologist.

[13]  K. Shokat,et al.  Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile , 2022, Journal of the American Chemical Society.

[14]  E. Petricoin,et al.  Functional and biological heterogeneity of KRASQ61 mutations , 2022, Science Signaling.

[15]  M. Meyerson,et al.  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D mutated non-small cell lung cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  P. Jänne,et al.  Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. , 2022, The New England journal of medicine.

[17]  F. Dekker,et al.  Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Fox,et al.  Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. , 2022, The New England journal of medicine.

[19]  K. Haigis,et al.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. , 2022, Cancer discovery.

[20]  P. Jänne,et al.  Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers , 2022, Nature.

[21]  M. Levy,et al.  Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss). , 2022, Journal of Clinical Oncology.

[22]  A. Redig,et al.  Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  A. Kamb,et al.  Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity , 2022, Cancer research communications.

[24]  Cunchuan Wang,et al.  Prognostic value of SMAD4 in resectable pancreatic cancer , 2022, Postępy Higieny i Medycyny Doświadczalnej.

[25]  J. Sicklick,et al.  Targeting ARID1A mutations in cancer. , 2021, Cancer treatment reviews.

[26]  E. O’Reilly,et al.  Targeting DNA damage repair pathways in pancreas cancer , 2021, Cancer and Metastasis Reviews.

[27]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[28]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  L. Matrisian,et al.  Estimated Projection of US Cancer Incidence and Death to 2040 , 2021, JAMA network open.

[30]  Xiaowu Xu,et al.  Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications , 2021, Acta Pharmacologica Sinica.

[31]  R. DePinho,et al.  Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. , 2020, Cancer discovery.

[32]  R. DePinho,et al.  Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment. , 2020, Cancer discovery.

[33]  K. Pradhan,et al.  Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis , 2019, bioRxiv.

[34]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[35]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[36]  Edward S. Kim,et al.  Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. , 2019, JCO precision oncology.

[37]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[38]  J. Gaedcke,et al.  ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells , 2019, Clinical Epigenetics.

[39]  C. Der,et al.  RAS Mutations Are Not Created Equal. , 2019, Cancer discovery.

[40]  A. Futreal,et al.  Building a data foundation: How MD Anderson and Palantir are partnering to accelerate research and improve patient care. , 2019, Journal of Clinical Oncology.

[41]  Alfredo López,et al.  The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma. , 2019, Journal of Clinical Oncology.

[42]  D. Šálek,et al.  ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients , 2019, Leukemia & lymphoma.

[43]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[44]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[45]  H. Seno,et al.  ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. , 2018, Gastroenterology.

[46]  E. Petricoin,et al.  Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative , 2018, Clinical Cancer Research.

[47]  W. Hahn,et al.  Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma , 2017, JAMA oncology.

[48]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[49]  Gun Ho Jang,et al.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns , 2016, Nature.

[50]  Hannah C. Beird,et al.  Tackling "big data" for accelerating cancer research. , 2016 .

[51]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[52]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[53]  Li Wei,et al.  Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis12 , 2016, Translational oncology.

[54]  Wei Zhang,et al.  ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. , 2015, Cancer discovery.

[55]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[56]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[57]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[58]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[59]  J. Hoheisel,et al.  Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival , 2013, PloS one.

[60]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[61]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[62]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[63]  Manuel Hidalgo,et al.  Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer , 2011, Proceedings of the National Academy of Sciences.

[64]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[65]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[66]  R. Hruban,et al.  Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion , 2005, Modern Pathology.

[67]  J. Cameron,et al.  Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: A potential new target for therapy , 2005, Cancer biology & therapy.

[68]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[69]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[70]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[71]  Nicole M. Baker,et al.  Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. , 2019, Cancer discovery.

[72]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.